It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

As GLP-1 weight loss drugs fly off shelves, Kourtney Kardashian Barker is getting in on the hustle — well, sort of. As ...

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

In our view, we believe the market misunderstands the long-term clinical impact of glucagon-like-peptide-1 (GLP-1s) on ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

"Weight loss medications are not one size fits all and patients should always discuss options with a trusted medical professional," one expert told Newsweek.